Innoviva Inc.

News & Events

Press Releases

In The Media

1. FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

   Business Wire JUN 12, 2025 7:00 AM EDT
   FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Ad...
   READ ARTICLE

2. Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

   Business Wire JUN 10, 2025 6:00 AM EDT
   In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae ...
   READ ARTICLE

3. Innoviva to Participate in Upcoming Investor Conferences

   Business Wire JUN 3, 2025 7:00 AM EDT
   Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a divers...
   READ ARTICLE

4. ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

   Business Wire MAY 20, 2025 6:00 AM EDT
   ZEVTERA is the first and only U.S. Food and Drug Administration-approved cephalosporin indicated ...
   READ ARTICLE

5. Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

   Business Wire MAY 7, 2025 4:05 PM EDT
   Core royalty platform maintained strong performance, generating $61.3 million in revenue ...
   READ ARTICLE

6. Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

   PR Newswire MAR 12, 2025 5:08 PM EDT
   Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva PR ...
   READ ARTICLE

7. Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

   Business Wire MAR 5, 2025 7:00 AM EST
   Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a divers...
   READ ARTICLE

8. Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

   Business Wire FEB 26, 2025 4:04 PM EST
   Core royalty platform continues to deliver with GSK royalties of $66.0 million for the fourth qua...
   READ ARTICLE

9. Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

   Business Wire FEB 6, 2025 7:00 AM EST
   Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a divers...
   READ ARTICLE

10. Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

    Business Wire DEC 16, 2024 7:00 AM EST
    Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasd...
    READ ARTICLE